key: cord-0744193-lg83yae0
authors: Kubale, J.; Gleason, C. R.; Carreno, J. M.; Srivastava, K.; PARIS Study Team,; Gordon, A.; Krammer, F.; Simon, V.
title: SARS-CoV-2 spike-binding antibody longevity and protection from re-infection with antigenically similar SARS-CoV-2 variants
date: 2022-03-30
journal: nan
DOI: 10.1101/2022.03.28.22273068
sha: 7a5451e406b253c8d33eab6f22837ca8e146d96c
doc_id: 744193
cord_uid: lg83yae0

The PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2) cohort follows health care workers with and without documented coronavirus disease 2019 (COVID-19) since April 2020. We report our findings regarding SARS-CoV-2 spike binding antibody stability and protection from infection in the pre-variant era. We analyzed data from 400 healthcare workers (150 seropositive and 250 seronegative at enrollment) for a median of 84 days. The SARS-CoV-2 spike binding antibody titers were highly variable with antibody levels decreasing over the first three months, followed by a relative stabilization. We found that both more advanced age (>40 years) and female sex were associated with higher antibody levels (1.6-fold and 1.4-fold increases, respectively). Only six percent of the initially seropositive participants "seroreverted". We documented a total of 11 new SARS-CoV-2 infections (ten naive participants, one previously infected participant without detectable antibodies, p<0.01) indicating that spike antibodies limit the risk of re-infection. These observations, however, only apply to SARS-CoV-2 variants antigenically similar to the ancestral SARS-CoV-2 ones. In conclusion, SARS-CoV-2 antibody titers mounted upon infection are stable over several months in most people and provide protection from infection with antigenically similar viruses.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the 52 coronavirus disease 2019 pandemic with over 430 million infections (WHO 53 dashboard, February 25 th 2022) since it emerged in late 2019 (1, 2). In the vast majority of 54 individuals, infection with SARS-CoV-2 leads to the induction of a specific adaptive immune 55 response including spike binding as well as neutralizing antibodies (3, 4) . Indeed, we found that 56 over 90% of individuals infected during the first wave in New York City (NYC) had robust 57 antibody titers as measured using an enzyme-linked immunosorbent assay (ELISA, >30,000 58 cross-sectional measurements) (4, 5). The durability and protective effect of such antibody 59 responses remains a topic of active investigation even as we move into the third year of the 60

pandemic. An initial study (6) reported fast waning of SARS-CoV-2 binding antibodies but others 61 report spike binding IgG antibodies being detectable months after infection (7) (8) (9) . 62

The first SARS-CoV-2 infection in New York State was officially detected at the Mount 63

Sinai Health System in NYC on February 29 th , 2020 although SARS-CoV-2 had likely been 64 introduced to the local communities weeks to months earlier (10, 11). Indeed, the New York 65 metropolitan area emerged as one of the early COVID-19 epicenters in the US. This initial 66 COVID-19 wave was exponential in growth and nearly overwhelmed our local health care 67 systems due to the high number of patients with severe COVID-19 manifestations resulting in 68 infection fatality rates ranging between 1 and 1.5% (11, 12) . It was at that point in time (April 69 2020) that we started enrollment for the PARIS (Protection Associated with Rapid Immunity to 70 SARS-CoV-2) cohort to follow health care workers (HCWs) of the Mount Sinai Health System 71 with and without documented COVID-19 over time. Full-length spike binding IgG antibody titers 72

were measured every two to four weeks using a sensitive and specific quantitative ELISA (13) . 73

In addition, data on potential exposures as well as clinical signs and symptoms suggestive of 74 SARS-CoV-2 infection were collected at the same time intervals. 75 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 30, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 

Description of the PARIS cohort: The PARIS study enrolled healthcare workers with and 79 without prior SARS-CoV-2 infection to study the durability and effectiveness of the immune 80 response to SARS-CoV-2. A total of 501 participants were enrolled between April 2020 and 81

August 2021. The study protocol was reviewed and approved by the Mount Sinai Hospital 82

Institutional Review Board (IRB-20-03374). All participants provided written informed consent. 83

Samples were coded prior to processing and testing. Blood was collected at 2-4 week intervals 84 regardless of the serostatus at enrollment. For this analysis, the cohort was restricted to 400 85 participants enrolled prior to SARS-CoV-2 vaccination with, at least, four weeks of follow-up or 86 two study visits prior to vaccination. At the time of enrollment, 150/400 participants were 87 seropositive for SARS-CoV-2 spike binding antibodies while 250/400 were seronegative. Most 88 participants had no known immunosuppressive conditions/co-morbidities. We used the data 89 from 2,106 distinct study visits from these 400 participants to evaluate risk of SARS-CoV-2 90 infection and seroreversion. From this dataset, we selected a subset of 137 participants with 91 known dates of COVID-19 (symptom onset, positive SARS-CoV-2 nucleic acid amplification test 92 (NAAT), or positive SARS-CoV-2 antibody test results) and, at least, two pre-vaccine study 93 visits with SARS-CoV-2 antibody measurements. The data of 813 distinct study visits from these 94 137 seropositive participants provide the basis for the modeling SARS-CoV-2 spike-binding IgG 95 antibody durability. 96 97 Identification of new SARS-CoV-2 infections in PARIS. One of the 11 participants who were 98 infected during the observation period was diagnosed as part of the study using viral diagnostic 99 NAAT while nine participants tested positive for SARS-CoV-2 outside of the Mount Sinai Health 100 System. One asymptomatic infection was identified by seroconversion (from negative to a titer 101 of 1:400). 102 103 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 30, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 SARS-CoV-2 full-length spike binding antibody measurements. Antibody titers were 104 determined using a two-step ELISA protocol (13) in which sera are screened at a single dilution 105

(1:50) for IgG against the recombinant receptor binding domain (RBD) of the spike protein from 106 SARS-CoV-2, followed by detection of antibodies against the full-length spike protein. End-point 107 titers were determined by serially diluting sera (from 1:80 to 1:102,400). Briefly, 96-well 108 microtitre plates (Thermo Fisher) were coated with 50 μl/well of recombinant RBD (2 μg/ml) 109 overnight at 4 °C. Plates were washed three times with phosphate-buffered saline (PBS; Gibco) 110 supplemented with 0.1% Tween-20 (PBS-T; Fisher Scientific) using an automatic plate washer 111 (BioTek). Plates were then blocked with PBS-T containing 3% milk powder (American Bio) for 1 112 hour. Sera was heat-inactivated and serially diluted (3-fold) in PBS-T 1%-milk powder, starting 113 at 1:50 initial dilution for RBD ELISA and at 1:80 dilution for full-length spike ELISA. Samples 114 were added to the plates and incubated for 2-hours. Plates were washed three times with PBS-115 T and 50 μl/well of anti-human IgG (Fab-specific) horseradish peroxidase antibody (produced in 116 goat; Sigma, A0293) diluted to 1:3,000 in PBS-T, 1% milk powder, were added to each well. 117

After 1-hour incubation at room temperature, plates were washed three times with PBS-T and 118 100 μl/well of SigmaFast o-phenylenediamine dihydrochloride (Sigma) were added for 10min, 119 followed by addition of 50 μl/well of 3M hydrochloric acid (Thermo Fisher) to stop the reaction. 120

Optical density was measured at a wavelength of 490 nm using a plate reader (BioTek). 121

Endpoint titers, expressed as the last dilution before the signal dropped below an OD490nm of 122 0.15, were calculated in excel and data was plotted using GraphPad Prism 9. 123 124 Assessment and modeling of SARS-CoV-2 Spike binding antibody durability over time. 125

To assess how spike antibody titers changed over time we fit an additive mixed model using the 126 mgcv package (version 1.8-36) for R (version 4.1.1). Participants were excluded from the model 127 if they never developed a detectable titer (at least 1:80) during follow-up or if the data regarding 128 when they were infected (illness onset, NAAT positive, or antibody positive date) was missing. 129 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 30, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Day 0 was defined as the reported symptom onset date or the date of positive SARS-CoV-2 130 diagnostic test. 131

Spike titers (ranging from 1:80 to 1:6,400) were transformed to the log2 scale so that a 1-unit 132 increase corresponded to a doubling of antibody titer. Sex (female, male), age (<40 years, 40+ 133 years), and baseline titer (<1:800, ≥1:800) were included as covariates in the model, along with 134 a random intercept for participant ID to account for repeated measures. Finally, a penalized 135 spline term was included to model antibody titer over time. We fit this model in two ways: 1) 136 assuming that antibody decay occurred at the same rate over time regardless of baseline titer, 137

2) allowing antibody decay over time to vary by baseline titer. In the second model a distinct 138 smoothing function was fit for each baseline titer group. Data is available upon request, and the 139 code used for modeling is available on GitHub at https://github.com/jkubale/paris. CoV-2 infections were identified by positive NAAT or by SARS-CoV-2 antibody seroconversion. 151

The participant immune status was based on the most recent spike binding antibody titer 152 preceding the infection. Participants with detectable spike binding antibody titers were 153 compared to those without detectable titers using Fisher's Exact Test. All analyses were 154 performed using R version 4.1.1. 155 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 30, 2022. ; https://doi.org/10.1101/2022.03.28.22273068 doi: medRxiv preprint

We analyzed the spike binding IgG antibody levels of 400 PARIS participants with (N: 157 150) or without previous COVID-19 (N: 250) collected every two to four weeks for a median of 158 84 days (IQR: 55-169) from April 2020 to August 2021. The majority of participants were female 159 (68%) with a median age of 35 years (range: 19-75; interquartile range [IQR]: 30-45). The 160 demographics of the cohort are summarized in Table 1 . Approximately a third of the participants 161 self-reported as performing high-risk tasks as part of their work assignments. Most participants 162 with spike binding antibodies at study enrollment (92.7%, 139/150) were infected during the first 163 pandemic wave when NYC was one of the epicenters of the pandemic (March-May 2020). Of 164 the remaining 11 participants, seven were infected in the summer and fall of 2020 prior to 165 enrolling into PARIS and four participants did not recall having any symptoms suggestive of 166 COVID-19. Two PARIS cohort datasets were used to analyze durability and effectiveness of 167 serological responses (Protection Dataset, Antibody Durability Dataset, Figure 1A , Table 1 ). 168

To model spike-binding antibody kinetics, we analyzed a total of 813 distinct spike 169 binding measurements from 137 participants (median: five study visits; IQR: 4-8 visits per 170 participant, longitudinal follow-up of two to six months up to 400 days post-infection, see Table  171 1, Supplemental Figure 1 ). The date of symptom onset or positive NAAT was used as Day 0 172 when available. Alternatively, we used the date of first positive SARS-CoV-2 antibody assay as 173

Day 0 for 21 participants. Spike binding IgG antibody titers were highly variable among COVID-174 19 survivors, with titers ranging between 1:80 and 1:6,400. The majority (59.1%) of participants 175 had SARS-CoV-2 binding antibody titers above 1:800 at their baseline visit. We noted that the 176 antibody levels decreased over the first three months, followed by a relative stabilization that 177 persisted up to one year post-infection ( Figure 1B) . Given the large variation in the initial 178 antibody levels, we modeled whether the slopes for those with titers above 1:800 were different 179 from the slopes measured for those with lower antibodies (less than 1:800). SARS-CoV-2 spike 180 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 30, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 binding antibody kinetics between the two groups were comparable, with the initial decay being 181 more pronounced in the high antibody group (Figure 1C ). 182

We next tested whether demographic variables such as sex or age were associated with 183 the durability of spike antibody durability by modeling the impact of sex and age on antibody 184 levels over the course of the observation period. We found that more advanced age (e.g., 40 185 years or older) was associated with 1.62-fold higher antibody levels (95% CI: 1.20-2.19) 186 compared to younger participants. Sex was also associated with the level of SARS-CoV-2 spike 187 antibodies, with antibody levels being 1.40-fold higher in female participants (95% CI: 1.03-1.92) 188 than male participants (Supplementary Table S1 ). 189

All the participants with documented SARS-CoV-2 infection also mounted detectable 190 antibody responses but we wondered whether seropositive individuals would turn seronegative 191 during the observation period. We found that 6% (8/137) by an initial strong peak, driven by short-lived plasmablasts in the peripheral blood circulation, 217 followed by a decline and an eventual stabilization at a level of antibody that is produced by 218 long-lived plasmablasts in the bone marrow (16-18). This was exactly the pattern that we 219 observed in our analysis: high SARS-CoV-2 antibody titers declined initially but stabilized over 220 the following months. Overall, seroreversion was rare with only 6% of the COVID-19 survivors 221 having antibody levels wane to below the level of detection of our sensitive full-length spike IG 222 binding antibody ELISA. Interestingly, there were large differences in the spike-binding antibody 223 titers across participants with those 40 years and older having higher antibody titers compared 224 to younger individuals. This phenomenon has been observed before (19, 20) . Our observation 225 that female participants have higher antibody titers than male participants stands in contrast to 226 several previous studies reporting that males have higher SARS-CoV-2 antibody levels (4). The 227 PARIS cohort comprises mostly younger and overall healthy health care workers with almost 228 exclusively mild infections, so it is conceivable that this sex difference becomes less apparent 229 when more severe COVID-19 manifestations known to result in higher antibody levels (20) are 230 included in the analysis. Of note other than the magnitude, there was no sizable difference in 231 the kinetics of antibody levels depending on age or sex. Additional studies in longitudinal 232 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 30, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 cohorts with as frequent sampling as done in the PARIS cohort are needed to independently 233 replicate our observations. 234

Several studies from the pre-(20-26) and post-Delta (B.1.617.2) (27, 28) era suggest 235 that protection from reinfection ranges around 80-90% if the circulating SARS-CoV-2 variants 236 are antigenically similar to the ones responsible for the initial infections. Only the appearance of 237

Omicron has led to an increase of reinfections (28, 29). Our cohort study supports this notion 238 since we did not document any reinfections in study participants who were previously infected 239 and maintained detectable levels of spike binding antibodies. Indeed, ten naïve individuals and 240 one individual with an initially low titer who sero-reverted prior to re-infection were infected 241 during the observation period. These findings suggest significant protection from reinfection and 242 hint at the importance of the level of spike-binding antibody titers in protection. Of note, the 243 presence of spike-binding antibodies was also correlated with protection in several other studies 244 (21, 30-32). Antibody titers against the receptor binding domain and the full-length spike, as well 245 as neutralizing antibodies, have recently been proposed as correlates of protection of vaccine 246 induced immunity (33-35). Importantly, the data in these studies were generated before the 247

Omicron variants started to circulate at larger scale in our community. Similarly, the current 248 analysis was conducted prior to the circulation of SARS-CoV-2 variants of concern in the NYC 249 metropolitan area. Our data underscores that spike binding antibodies protect against infection 250 with antigenically similar viral strains. Protection against heterologous, antigenically distinct 251 variants such as Omicron is likely limited based on the pronounced reduction in virus 252

This study has several strengths. First, the prospective nature of the cohort allowed us to 254 assess how antibody responses against SARS-CoV-2 following natural infection changed over 255 time. Second, the repeated sampling/testing of this study provides a perspective on a much 256 more granular scale than previous analyses. Finally, this study is based on data collected prior 257 to the introduction of SARS-CoV-2 vaccines and the wide circulation of variants of concern that 258 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 30, 2022. ; https://doi.org/10.1101/2022.03.28.22273068 doi: medRxiv preprint are highly antigenically distinct (e.g., Omicron). As such, it provides a useful baseline against 259 which newer data can be compared to answer important questions regarding the relative 260 severity of new variants, the strength and durability of antibody responses against SARS-CoV-2 261 variants, and the impact of immune histories on the breadth of immune responses. 262

This analysis did, however, also have a few limitations. First, since we started enrollment 263 during the first wave, a good portion of participants were unable to get molecular tests at the 264 time of infection and we relied on retrospective reports of clinical signs and symptoms 265 suggestive of COVID-19 for illness onset date. As such, recall bias in reported illness onset is a 266 possibility. However, we anticipate that this exerted only a minor impact on our conclusions 267

given the relatively homogenous exposures of participants who are all health care workers. 268

Second, with healthcare worker vaccination beginning in December 2020 we were unable to 269 effectively assess how circulating variants of concern may affect one's risk of re-infection In conclusion, our study shows that SARS-CoV-2 infection provides strong protection 274 from reinfection and this protection may be associated with the presence of spike binding 275

antibodies. In addition, it suggests that antibody levels induced by infection with ancestral 276 SARS-CoV-2 variants are relatively stable over time and that the rate of seroreversion is low 277 when measuring SARS-CoV-2 spike binding IgG antibodies. 278 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 30, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 

We thank the study participants for their generosity and willingness to participate in longitudinal 280 COVID-19 research studies. None of this work would be possible without their contributions. for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Third Rock Ventures, 299

Seqirus and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models 300 of SARS-CoV-2. Aubree Gordon serves on a scientific advisory board for Janssen and has 301 consulted for Gilead Sciences. 302 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 30, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 

Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of 370 protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in 371 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 30, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 30, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 

A serological assay to detect SARS-CoV-2 seroconversion in humans

Spike Immunoglobin G Antibodies to SARS-CoV-2 Among Health Care Workers With Prior 340

Introductions and early spread of SARS-CoV-2 in the New York City area

The germinal centre B cell response to SARS-CoV-2